Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer

Goldgar, 1994, Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands, J Natl Cancer Inst, 86, 1600, 10.1093/jnci/86.21.1600 Mucci, 2016, Familial risk and heritability of cancer among twins in Nordic countries, JAMA, 315, 68, 10.1001/jama.2015.17703 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144 Cancer Genome Atlas Research Network, 2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025 Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Romanel, 2015, Plasma AR and abiraterone-resistant prostate cancer, Sci Transl Med, 7, 312re10, 10.1126/scitranslmed.aac9511 Wyatt, 2016, Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer, JAMA Oncol, 2, 1598, 10.1001/jamaoncol.2016.0494 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815 Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022 Chedgy, 2016, Moving toward personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-null neuroendocrine prostate cancer, Clin Genitourin Cancer, 14, e233, 10.1016/j.clgc.2015.12.023 Mateo, 2017, DNA repair in prostate cancer: biology and clinical implications, Eur Urol, 71, 417, 10.1016/j.eururo.2016.08.037 Youngren, 2015, Abstract A12: identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team, Clin Cancer Res, 21, A12, 10.1158/1557-3265.PMS14-A12 Cooperberg, 2005, The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy, J Urol, 173, 1938, 10.1097/01.ju.0000158155.33890.e7 Hotte, 2010, Current management of castrate-resistant prostate cancer, Curr Oncol, 17, S72, 10.3747/co.v17i0.718 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Langmead, 2012, Fast gapped-read alignment with Bowtie 2, Nat Methods, 9, 357, 10.1038/nmeth.1923 Faust, 2014, SAMBLASTER: fast duplicate marking and structural variant read extraction, Bioinformatics, 30, 2503, 10.1093/bioinformatics/btu314 Quinlan, 2010, BEDTools: a flexible suite of utilities for comparing genomic features, Bioinformatics, 26, 841, 10.1093/bioinformatics/btq033 Wang, 2010, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data, Nucleic Acids Res, 38, e164, 10.1093/nar/gkq603 Edwards, 2010, Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis, Br J Cancer, 103, 918, 10.1038/sj.bjc.6605822 Crook, 2012, Intermittent androgen suppression for rising PSA level after radiotherapy, N Engl J Med, 367, 895, 10.1056/NEJMoa1201546 Hussain, 2016, 5010 Alix-Panabières, 2016, Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy, Cancer Discov, 6, 479, 10.1158/2159-8290.CD-15-1483